Progress in the application of drug-coated balloon in the treatment of in-stent restenosis
LIU Juncheng1 SI Chunying2 WANG He2 XIE Jinhong2▲ GUAN Huaimin2▲
1.The First Clinical Medical College, He′nan University of Chinese Medicine, He′nan Province, Zhengzhou 450000, China;
2.Ward 3, Cardiovascular Medicine Department, the First Affiliated Hospital of He′nan University of Chinese Medicine, He′nan Province, Zhengzhou 450000, China
Abstract：After percutaneous coronary intervention, in-stent restenosis is the most common complication in patients with coronary atherosclerosis, and its exact pathogenesis is unclear. The emergence of drug-eluting balloon provids a new method for coronary artery intervention treatment. However, there is still a lack of consensus on clinical application and prognostic evaluation, and especially the application effect of coronary in-stent restenosis is controversial. This article discusses the clinical application of drug-coated balloons in the treatment of coronary in-stent restenosis.
刘俊呈1 司春婴2 王贺2 解金红2▲ 关怀敏2▲. 药物涂层球囊在支架内再狭窄治疗中的应用进展[J]. 中国医药导报, 2019, 16(26): 33-36.
LIU Juncheng1 SI Chunying2 WANG He2 XIE Jinhong2▲ GUAN Huaimin2▲. Progress in the application of drug-coated balloon in the treatment of in-stent restenosis. 中国医药导报, 2019, 16(26): 33-36.
[1] 陈伟伟，高润霖，刘力生，等.《中国心血管病报告2017》概要[J].中国循环杂志，2018，33（1）：1-8.
[2] Kalra A，Rehman H，Khera S，et al. New-Generation Coronary Stents：Current Data and Future Directions [J]. Curr Atheroscler Rep，2017，19（3）：14.
[3] Cassese S，Byrne RA，Tada T，et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography [J]. Heart，2014，100（2）：153-159.
[4] Dangas GD，Claessen BE，Caixeta A，et al. In-Stent Restenosis in the Drug-Eluting Stent Era [J]. J Am Coll Cardiol，2010，56（23）：1897-1907.
[5] Guildford ALS，Tewart HJS，Morris C，et al. Substrate-induced phenotypic switches of human smooth muscle cells：An in vitro study of in-stent restenosis activation pathways [J]. J R Soc Interface，2010，8（58）：641-649.
[6] Cremers B，Toner JL，Schwartz LB，et al. Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter [J]. Clin Res Cardiol，2012，101（6）：469-476.
[7] Indermuehle A，Bahl R，Lansky AJ，et al. Drug-eluting balloon angioplasty for in-stent restenosis：a systematic review and meta-analysis of randomised controlled trials [J]. Heart，2013，99（5）：327-333.
[8] Joshua P，Barbash IM，Waksman R，et al. The current status of drug-coated balloons in percutaneous coronary and peripheral interventions [J]. Eurointervention，2013，9（8）：979-988.
[9] Scheller B，Hehrlein C，Bocksch W，et al. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter [J]. Clin Res Cardiol，2008，97（10）：773-781.
[10] Ang H，Lin J，Huang YY，et al. Drug-Coated Balloons： Technologies and Clinical Applications [J]. Curr Pharm Des，2018，24（4）：381-396.
[11] Kolachalama VB，Pacetti SD，Franses JW，et al. Mechanisms of Tissue Uptake and Retention in Zotarolimus-Coated Balloon Therapy [J]. Circulation，2013，127（20）：2047-2055.
[12] Lee JM，Park J，Kang J，et al. Comparison among drug-eluting balloon，drug-eluting stent，and plain balloon angioplasty for the treatment of in-stent restenosis：a network meta-analysis of 11 randomized, controlled trials [J]. JACC Cardiovasc Interv，2015，8（3）：382-394.
[13] Siontis GCM，Piccolo R，Praz F，et al. Percutaneous Coronary Interventions for the Treatment of Stenoses in Small Coronary Arteries：A Network Meta-Analysis [J]. JACC Cardiovasc Interv，2016，9（13）：1324-1334.
[14] 尹秋林.药物涂层球囊导管在冠脉支架内再狭窄治疗中的临床疗效研究[J].现代诊断与治疗，2017（20）：3836-3837.
[15] Brodmann M，Werner M，Meyer DR，et al. Sustainable Antirestenosis Effect With a Low-Dose Drug-Coated Balloon：The ILLUMENATE European Randomized Clinical Trial 2-Year Results [J]. JACC Cardiovasc Interv，2018，11：2357-2364.
[16] Colleran R，Joner M，Kufner S，et al. Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosis：A pooled analysis of the Intracoronary Stenting and Angiographic Results：Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 3 and 4（ISAR-DESIRE 3 and ISAR-DESIRE 4）trials [J]. Int J Cardiol，2018， 252：57-62.
[17] Alfonso F，Perez-Vizcayno MJ，Cardenas A，et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis：the RIBS V Clinical Trial（Restenosis Intra-stent of Bare Metal Stents：paclitaxel-eluting balloon vs.everolimus-eluting stent）[J]. J Am Coll Cardiol，2014，63（14）：1378-1386.
[18] Jensen CJ，Richardt G，T?觟lg R，et al. Angiographic and clinical performance of a paclitaxel coated balloon compared to a 2nd generation sirolimus eluting stent in patients with in-stent restenosis- the BIOLUX randomized controlled trial [J]. Eurointervention，2018，14（10）：1096-1103.
[19] Rosenberg M，Waliszewski M，Chin K，et al. Prospective，large-scale multicenter trial for the use of drug-coated balloons in coronary lesions：The DCB-only All-Comers Registry [J]. Catheter Cardiovasc Interv，2018，93（2）：181-188.
[20] Xu B，Qian J，Ge J，et al. Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial：A prospective，multicenter，randomized trial for the treatment of drug-eluting stent in-stent restenosis [J]. Catheter Cardiovasc Interv，2016，87（S1）：624-629.
[21] Baan J，Claessen BE，Dijk BV，et al. A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis [J]. JACC Cardiovasc Interv，2017，11（3）：275-283.
[22] Lee JM，Rhee TM，Hahn JY，et al. Comparison of outcomes after treatment of instent restenosis using newer generation drug-eluting stents versus drug-eluting balloon：patient-level pooled analysis of Korean Multicenter in-Stent Restenosis Registry [J]. Int J Cardiol，2017， 230：181-190.
[23] Fukushima T，Ashikaga T，Yoshikawa S，et al. Effect of drug-coated balloon on stent restenosis，neointimal proliferation，and coronary dissection：an optical coherence tomography analysis [J]. Coron Artery Dis，2018，29（1）：39-45.
[24] Lee JH，Jung HW，Kim JS，et al. Different Neointimal Pattern in Early vs. Late In-Stent Restenosis and Clinical Outcomes After Drug-Coated Balloon Angioplasty-An Optical Coherence Tomography Study [J]. Circ J，2018，82（11）：2745-2752.
[25] Windecker S，Kolh P，Alfonso F，et al. 2014 ESC/EACTS Guidelines on myocardial revascularization：The Task Force on Myocardial Revascularization of the European Society of Cardiology（ESC）and the European Association for Cardio-Thoracic Surgery（EACTS）Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions （EAPCI） [J]. Eur Heart J，2014，35（37）：2541-619.
[26] 中华医学会心血管病学分会介入心脏病学组，中国医师协会心血管内科医师分会血栓防治专业委员会，中华心血管杂志编辑委员会.中国经皮冠状动脉介入治疗指南（2016）[J].中华心血管病杂志，2016，44（5）：382-400.
[27] 陈韵岱，王建安，刘斌，等.药物涂层球囊临床应用中国专家共识[J].中国介入心脏病学杂志，2016，24（2）：61-67.
2019, Vol. 16 
京公网安备 11010502046598号